UNLABELLED: Natural killer (NK) cells play crucial roles in innate immunity and express CD39 (Ecto-nucleoside triphosphate diphosphohydrolase 1 [E-NTPD1]), a rate-limiting ectonucleotidase in the phosphohydrolysis of extracellular nucleotides to adenosine. We have studied the effects of CD39 gene deletion on NK cells in dictating outcomes after partial hepatic ischemia/reperfusion injury (IRI). We show in mice that gene deletion of CD39 is associated with marked decreases in phosphohydrolysis of adenosine triphosphate (ATP) and adenosine diphosphate to adenosine monophosphate on NK cells, thereby modulating the type-2 purinergic (P2) receptors demonstrated on these cells. We note that CD39-null mice are protected from acute vascular injury after single-lobe warm IRI, and, relative to control wild-type mice, display significantly less elevation of aminotransferases with less pronounced histopathological changes associated with IRI. Selective adoptive transfers of immune cells into Rag2/common gamma null mice (deficient in T cells, B cells, and NK/NKT cells) suggest that it is CD39 deletion on NK cells that provides end-organ protection, which is comparable to that seen in the absence of interferon gamma. Indeed, NK effector mechanisms such as interferon gamma secretion are inhibited by P2 receptor activation in vitro. Specifically, ATPgammaS (a nonhydrolyzable ATP analog) inhibits secretion of interferon gamma by NK cells in response to interleukin-12 and interleukin-18, providing a mechanistic link between CD39 deletion and altered cytokine secretion. CONCLUSION: We propose that CD39 deficiency and changes in P2 receptor activation abrogate secretion of interferon gamma by NK cells in response to inflammatory mediators, thereby limiting tissue damage mediated by these innate immune cells during IRI.
UNLABELLED: Natural killer (NK) cells play crucial roles in innate immunity and express CD39 (Ecto-nucleoside triphosphate diphosphohydrolase 1 [E-NTPD1]), a rate-limiting ectonucleotidase in the phosphohydrolysis of extracellular nucleotides to adenosine. We have studied the effects of CD39 gene deletion on NK cells in dictating outcomes after partial hepatic ischemia/reperfusion injury (IRI). We show in mice that gene deletion of CD39 is associated with marked decreases in phosphohydrolysis of adenosine triphosphate (ATP) and adenosine diphosphate to adenosine monophosphate on NK cells, thereby modulating the type-2 purinergic (P2) receptors demonstrated on these cells. We note that CD39-null mice are protected from acute vascular injury after single-lobe warm IRI, and, relative to control wild-type mice, display significantly less elevation of aminotransferases with less pronounced histopathological changes associated with IRI. Selective adoptive transfers of immune cells into Rag2/common gamma null mice (deficient in T cells, B cells, and NK/NKT cells) suggest that it is CD39 deletion on NK cells that provides end-organ protection, which is comparable to that seen in the absence of interferon gamma. Indeed, NK effector mechanisms such as interferon gamma secretion are inhibited by P2 receptor activation in vitro. Specifically, ATPgammaS (a nonhydrolyzable ATP analog) inhibits secretion of interferon gamma by NK cells in response to interleukin-12 and interleukin-18, providing a mechanistic link between CD39 deletion and altered cytokine secretion. CONCLUSION: We propose that CD39deficiency and changes in P2 receptor activation abrogate secretion of interferon gamma by NK cells in response to inflammatory mediators, thereby limiting tissue damage mediated by these innate immune cells during IRI.
Authors: Françoise Wilkin; Patrick Stordeur; Michel Goldman; Jean-Marie Boeynaems; Bernard Robaye Journal: Eur J Immunol Date: 2002-09 Impact factor: 5.532
Authors: Jean Sévigny; Christian Sundberg; Norbert Braun; Olaf Guckelberger; Eva Csizmadia; Imrana Qawi; Masato Imai; Herbert Zimmermann; Simon C Robson Journal: Blood Date: 2002-04-15 Impact factor: 22.113
Authors: Maria Serena Longhi; Simon C Robson; Steven H Bernstein; Sara Serra; Silvia Deaglio Journal: J Mol Med (Berl) Date: 2013-01-06 Impact factor: 4.599
Authors: René Fahrner; Felix Dondorf; Michael Ardelt; Utz Settmacher; Falk Rauchfuss Journal: World J Gastroenterol Date: 2016-07-21 Impact factor: 5.742
Authors: Yuan Zhai; Henrik Petrowsky; Johnny C Hong; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Nat Rev Gastroenterol Hepatol Date: 2012-12-11 Impact factor: 46.802
Authors: Jan Schulte Am Esch; Simon C Robson; Moritz Schmelzle; Constanze Duhme; Wolfgang Junger; Steven D Salhanick; Yu Chen; Yan Wu; Vasilis Toxavidis; Eva Csizmadia; Lihui Han; Shu Bian; Günter Fürst; Martina Nowak; Seth J Karp; Wolfram T Knoefel Journal: Ann Surg Date: 2013-04 Impact factor: 12.969
Authors: Martina Nowak-Machen; Moritz Schmelzle; Dusan Hanidziar; Wolfgang Junger; Mark Exley; Leo Otterbein; Yan Wu; Eva Csizmadia; Glen Doherty; Michail Sitkovsky; Simon C Robson Journal: Am J Respir Cell Mol Biol Date: 2013-05 Impact factor: 6.914